Gilead Sciences, Inc. (GILD)
After hours:
| Previous Close | 67.72 |
| Open | 67.71 |
| Bid | 67.88 x 400 |
| Ask | 67.91 x 400 |
| Day's Range | 67.38 - 68.04 |
| 52 Week Range | 64.33 - 87.87 |
| Volume | |
| Avg. Volume | 6,930,088 |
| Market Cap | 84.593B |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 188.61 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (4.55%) |
| Ex-Dividend Date | Jun 14, 2024 |
| 1y Target Est | N/A |
- Business Wire
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
FOSTER CITY, Calif., May 18, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are cu
- Business Wire
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
- ACCESSWIRE
Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care
NORTHAMPTON, MA / ACCESSWIRE / May 14, 2024 / Olivia Sloan was pursuing a career in health policy and research when her father was diagnosed with non-Hodgkin lymphoma. The devastating news put her work on hold as she returned home to Santa Fe, New ...
